Colon Cancer

Image courtesy Everist Genomics

More Positive Results For Everist Genomics’ OncoDefender-CRC

Everist Genomics, a developer of personalized medicine, announced the publication of positive results from an international validation study which demonstrated that the OncoDefender-CRC colorectal cancer test result is a significant independent predictor of recurrence in node-negative, invasive colorectal cancer patients.

WWJ Newsradio 950–06/04/2012


New Cancer Recurrence Test From Ann Arbor Firm

Ann Arbor-based Everist Genomics announced the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay, the first and only molecular prognostic test capable of accurately predicting the risk of recurrence of cancer in patients previously treated […]



UM Cancer Center Gets $10.7M Fed Grant

The University of Michigan Comprehensive Cancer Center has received a five-year $10.7 million grant from the National Cancer Institute to study colorectal and pancreatic cancer.



UM Study Finds Surgery Complicaitons Lead To Chemo Delay

Patients who have complications after colorectal cancer surgery are less likely to get chemotherapy, even when it is clearly recommended for their diagnosis, a new study from the University of Michigan Comprehensive Cancer Center finds. […]